

<p>Nature of transaction:</p>	<p>(a) Exercise of 1,000,000 GENWA warrants at 7.75 cents per share and converted into 1,000,000 ordinary shares.</p>	<p>(b) Purchase of 5,000,000 GENWA warrants as part of Warrant tender process as announced to the NZX by General Capital Limited on 24 Sep 2019 and settling on 30 Sep 2019.</p>	<p>(c) Purchase of 10,000,000 GENWA warrants as part of Warrant tender process as announced to the NZX by General Capital Limited on 24 Sep 2019 and settling on 30 Sep 2019.</p>		
<p>Name of any other party or parties to the transaction (if known): The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration: Number of financial products to which the transaction related:</p>	<p>(a) N/A (a) \$77,500 (7.75 cents per share) (a) 1,000,000</p>	<p>(a) N/A (b) Held by General Capital Limited on behalf of ineligible shareholders. (a) \$77,500 (7.75 cents per share) (b) \$2,000 (a) 1,000,000 (b) 5,000,000</p>	<p>(c) Held by General Capital Limited on behalf of ineligible shareholders. (c) \$2,000 (c) 10,000,000</p>		
<p>If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—</p>	<p>Transactions during closed period Directors and senior managers approved by the Board to exercise warrants and participate in the warrant tender process. 30/08/2019</p>	<p>Transactions during closed period Directors and senior managers approved by the Board to exercise warrants and participate in the warrant tender process. 30/08/2019</p>	<p>Transactions during closed period Directors and senior managers approved by the Board to exercise warrants and participate in the warrant tender process. 30/08/2019</p>	<p>Transactions during closed period</p>	<p>Transactions during closed period</p>
<p>Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period: Date of the prior written clearance (if any):</p>	<p>Directors and senior managers approved by the Board to exercise warrants and participate in the warrant tender process. 30/08/2019</p>	<p>Directors and senior managers approved by the Board to exercise warrants and participate in the warrant tender process. 30/08/2019</p>	<p>Directors and senior managers approved by the Board to exercise warrants and participate in the warrant tender process. 30/08/2019</p>	<p>Directors and senior managers approved by the Board to exercise warrants and participate in the warrant tender process.</p>	<p>Directors and senior managers approved by the Board to exercise warrants and participate in the warrant tender process.</p>

Certification

I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorized to make this disclosure by all persons for whom it is made.

Signature of director or officer:

Date of signature:

or

Signature of person authorized to sign on behalf of director or officer:



Date of signature:

3/10/2019

Name and title of authorized person:

Jonathan Clark
Chief Financial Officer